A global AIDS vaccine conference this week will seek fresh strategies against the HIV virus, with experts weighing the value of basic laboratory research against large-scale human clinical trials after a string of disappointments. Approaches now has changed focusing on "neutralizing antibodies" that would allow the human immune system to block infection completely, are likely to take over existing models that seek to manage infection after it occurs. Fundamentally we don't understand enough about the human immune system and we don't know how the immune system deals with HIV. The two stalled vaccines had been produced, one developed by drug giant Merck and the other by U.S. government researchers, both aimed to fight AIDS by encouraging so-called cell-mediated immunity, jump-starting T-cells to tackle the virus and stop or slow the progress of HIV-related disease. The AIDS virus infects an estimated 33 million people globally and has killed 25 million since it was identified in the 1980s. Cocktails of drugs can control the virus but there is no cure and remedies. Focus was now on another approach to fighting HIV: lab work to discover how to help the body produce antibodies to prevent infection altogether. Neutralizing antibodies are a major component of almost all other vaccines. This year's disappointments should not be allowed to derail the pace of research. It's a continuous and iterative process. We have to accept that maybe it's not going to be possible. But until we know that, we have to keep trying. In my point of view, this effort must be a continuous process in order to obtain desired medicines for HIV and AIDS. In research, it is usual to face failure before getting actual result so that we must be patient and do not get disappointed easily as we are nearly approaching the succes. For sure each disease has its own remedies, only we need to find for the solution. Therefore we should be united in solving this problems in global context and sharing with others for the sake of the whole world.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment